AngioDynamics, Inc. (NASDAQ:ANGO), at 5.69% of his 13F, is fund manager Kotler’s fourth-largest stake. The company has garnered recent attention as it develops its “NanoKnife,” a minimally invasive cancer treatment tool that treats tumors that are too difficult or dangerous to remove surgically. The company’s sales are up nearly 50% this quarter, and a forward P/E of 29.08 indicates shares aren’t overly expensive. Additionally, a 3.18% uptick in the price of this stock since the start of the year has been a decent reward for Broadfin Capital thus far, but there’s more potential here.
The fifth-largest stock in the hedge fund is that of specialty biopharmaceutical company Santarus, Inc. (NASDAQ:SNTS). Up 234% over the past year, the price of Santarus’s shares has been increasing exponentially as of late. Buoyed by the recent success in clinical trials of UCERIS, a drug to treat ulcerative colitis, the stock is up 60% in 2013 alone. Interestingly, Mr. Kotler, for his part, recently decreased his equity position by 56%.
For the healthcare inclined investor, Broadfin’s equity portfolio merits consideration. With his top five stock picks, Mr. Kotler has covered his bases within the industry, from a solid manufacturer of generic medications to a company developing experimental cancer treatments.
All of the stocks here, with the possible exception of Santarus—in which Brodfin has significantly decreased its stake—are set for steady growth. Angiodynamics and Natus are both poised to potentially develop breakthrough technologies to cure diseases, and thus are stocks that have the most inherent upside. Kotler appears to have cast his lot with the latter, and it’s quite possible that you may agree with him.